Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa

Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs GSK 3390107A (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 31 Oct 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.
    • 31 Oct 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top